NCT03101254View on ClinicalTrials.gov

LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

June 6, 2017

Primary Completion Date

October 21, 2020

Study Completion Date

November 11, 2020

Conditions
Melanoma
Interventions
DRUG

LY3022855

LY3022855 is a colony-stimulating factor-1 receptor (CSF-1R) inhibitor

DRUG

Vemurafenib

Vemurafenib is a BRAF inhibitor that works by blocking altered BRAF proteins from stimulating the growth of melanoma cancer cells

DRUG

Cobimetinib

Cobimetinib works by blocking a protein called MEK that has been known to promote melanoma growth

Trial Locations (1)

02215

Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT03101254 - LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma | Biotech Hunter | Biotech Hunter